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Context: Conventional glucocorticoid replacement therapy fails to mimic the physiological cortisol
rhythm, which may have implications for morbidity and mortality in patients with Addison’s disease.
Objective: The objective of the study was to compare the effects of continuous sc hydrocortisone
infusion (CSHI) with conventional oral hydrocortisone (OHC) replacement therapy.
Design, Patients, and Interventions: This was a prospective crossover, randomized, multicenter
clinical trial comparing 3 months of treatment with thrice-daily OHC vs CSHI. From Norway and
Sweden, 33 patients were enrolled from registries and clinics. All patients were assessed at baseline
and after 8 and 12 weeks in each treatment arm.
Main Outcome Measures: The morning ACTH level was the primary outcome measure. Secondary
outcome measures were effects on metabolism, health-related quality of life (HRQoL), sleep, and
safety.
Results: CSHI yielded normalization of morning ACTH and cortisol levels, and 24-hour salivary
cortisol curves resembled the normal circadian variation. Urinary concentrations of glucocorticoid
metabolites displayed a normal pattern with CSHI but were clearly altered with OHC. Several
HRQoL indices in the vitality domain improved over time with CSHI. No benefit was found for either
treatments for any subjective (Pittsburgh Sleep Quality Index questionnaire) or objective (actig-
raphy) sleep parameters.
Conclusion: CSHI safely brought ACTH and cortisol toward normal circadian levels without ad-
versely affecting glucocorticoid metabolism in the way that OHC did. Positive effects on HRQoL
were noted with CSHI, indicating that physiological glucocorticoid replacement therapy may be
beneficial and that CSHI might become a treatment option for patients poorly controlled on
conventional therapy. (J Clin Endocrinol Metab 99: 1665–1674, 2014)
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Over the past 60 years, glucocorticoid replacementin Addison’s disease (AD) has been virtually un-
changed. However, in recent decades a number of reports
have shown that AD patients have reduced health-related
quality of life (HRQoL) (1, 2), increased cardiovascular
risk factors (3, 4), risk of osteoporosis (5–7), and increased
mortality (8–10). Conventional replacement therapy in-
cludes oral hydrocortisone (OHC) or cortisone acetate
twice or thrice daily and the synthetic mineralocorticoid
fludrocortisone (11). Although this treatment replenishes
the adrenal hormones, it does not restore a normal cortisol
biorhythm. In fact, as judged by circulating cortisol levels,
this treatment renders the patient overtreated immediately
after oral administration and undertreated within a few
hours (12). During nighttime and early morning, the glu-
cocorticoid levels on OHC are undetectable, which con-
trasts the rise seen in healthy individuals (13). The hypo-
thalamus-pituitary-adrenal (HPA) axis is implicated in the
regulation of sleep (14, 15). In AD, low nighttime cortisol
levels, high ACTH levels, and presumably high levels of
CRH might lead to sleep disturbances, although no spe-
cific sleep disturbances have been described (16). Studies
in patients without AD have shown that normal nighttime
cortisol levels are necessary for normal rapid eye move-
ment sleep regulation (17). Compared with estimates of
endogenous cortisol production at 5.4–6.1 mg/m2d, AD
patients on conventional treatment receive too much glu-
cocorticoids (18). Taken together, these concerns have
sparked new interest in improving therapeutic regimens.
Efforts have been made to optimize replacement ther-
apy by various strategies (12, 19), but the optimal replace-
ment therapy is still unclear (20). A recent study demon-
strated that 24-hour cortisol exposure was reduced by
once-daily dual-release hydrocortisone, resulting in a
reduction of body weight, blood pressure (BP), and he-
moglobin A1c (HbA1c) (21). Although such treatment
successfully restored daytime cortisol levels to normal,
the late night increase in cortisol was not reestablished.
However, restoring the nighttime cortisol surge was ob-
tained by another modified-release hydrocortisone tab-
let (22, 23).
We previously showed that continuous sc hydrocorti-
sone infusion (CSHI) enables a fine-tuned control of glu-
cocorticoid delivery that allows restoration of the circa-
dian biorhythm (24). Over the last years, we know from
clinical experience and personal communication that CSHI
has been successfully applied as a last resort treatment
option in selected patients with poor functioning. Here we
report a clinical trial investigating the effects of imposing
a physiological circadian cortisol rhythm on patients with
AD. Specifically, we compared CSHI with OHC for effects
on hormones in the HPA axis, glucose, lipid and bone
metabolism, HRQoL, sleep, and safety.
Materials and Methods
Subjects and design
This multicenter, crossover, randomized clinical trial aimed
to compare the effects of 3 months on CSHI with 3 months on
thrice-daily OHC in Scandinavian AD patients (Figure 1). The
ACTH level, as a marker of overall glucocorticoid effects and
regulation, was the primary outcome. Safety and effects on other
metabolic parameters, HRQoL, and sleep were secondary end
points.
Eligible patients were identified from a patient registry (Reg-
istry of Organ-Specific Autoimmune Diseases) or from the hos-
pital diagnosis registries and invited to participate. The inclusion
criteria were verified autoimmune AD and aged 18–70 years.
Patients with concomitant diseases were required to be on stable
treatment during the study period. Exclusion criteria were dia-
betes mellitus, cardiovascular or malignant disease, pregnancy,
or pharmacological treatment with glucocorticoids or drugs that
interfere with cortisol metabolism (antiepileptics, rifampicin,
and St Johns wart). The patients should abstain from grapefruit
juice during the study period. After signing an informed consent
form and attending a screening visit, the patients attended a
practical course on pump treatment. The investigators consid-
ered withdrawal for safety reasons if a patient had major diffi-
culties managing the infusion pump. Before randomization, the
patients then underwent a period of dose adjustments of both
treatments (OHC and CSHI) as described below.
The study was approved by regional ethics committees and
the National Medicines Agencies in both countries (EudraCT
number 2009-010917-61). We conducted the study in accor-
Figure 1. Study design. Patients were screened for participation at visit 0, followed by individual dose adjustment for both OHC and CSHI. After a
washout period of a minimum of 1 month, the patients were randomized (visit A) to start with fixed doses of either treatment, lasting 12 weeks.
After a washout period of a minimum of 2 months (between visits C and D), the participants shifted to treatment protocol for another 12 weeks.
During washout periods, patients were treated with their pretrial replacement therapy.
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dance with the principles of good clinical practice (CPMP/ICH/
135/95) and the Declaration of Helsinki (1989 version).
Interventions
During CSHI, the patients received hydrocortisone (Solu-
Cortef Act-o-Vial; Pfizer Inc) administered by an insulin pump
(Dana Diabecare; SOOIL Development Co Ltd). The infusion
gear was applied as with an insulin pump. The patients were
instructed to clean the injection site with alcohol before needle
insertion and replace the hydrocortisone solution and the infu-
sion gear every 3 days. Initial doses were 10.5 mg/m2d with the
following infusion rate distribution: hours 8:00 AM to 2:00 PM,
0.5 mg/ m2h; 2:00–8:00 PM, 0.2 mg/m2h; 8:00 PM to 2:00 AM,
0.05 mg/m2h; and 2:00–8:00 AM, 1.0 mg/m2h. The CSHI doses
were adjusted according to salivary cortisol levels (h 6:00–
8:00 AM and 11:00–12:00 PM) and morning serum cortisol after
3–5 days. We aimed for a morning salivary cortisol in the middle
to upper reference range, a normal morning serum cortisol, and
an evening salivary cortisol in the lower reference range.
Oral treatment was weight adjusted and given three times
daily as hydrocortisone 5-mg tablets as suggested by Mah et al
(12). The oral doses were titrated according to a serum cortisol
nomogram 4 hours after the morning dose at days 3–5. We al-
lowed smaller dose adjustments for both treatments based on
best clinical judgment during dose titration, whereas all patients
were treated with individually adjusted fixed daily doses of both
treatments after randomization.
Assays
Fasting blood samples were drawn at 8:00 AM at baseline and
after 8 and 12 weeks on each treatment. The samples were stored
at 80°C until the end of trial. Salivary cortisol day profiles
(obtained at 8:00 AM, 9:30 AM, 11:00 AM, 12:30 PM, 2:00 PM,
3:30 PM,5:00 PM,6:30 PM,7:00 PM,9:00 PM,12:00 AM,3:00 AM,and
at 6:00 AM) were sampled at 8 and 12 weeks. The patients were
instructed to avoid eating, drinking, smoking, and tooth brush-
ing the last hour before each sampling. Cortisol and cortisone
(serum, 24 h urine and saliva) and their metabolites (urine) were
analyzed by liquid chromatography-mass spectrometry (25).
Salivary steroids were extracted as described by Methlie (26) and
tetrahydcortisol-d3 and tetrahydrocortisone-d5 were included
as internal standards for the metabolites. Cortisol binding glob-
ulin (CBG) in serum was measured by competitive RIA (DIA-
source immunoassay). Plasma ACTH was analyzed by chemi-
luminescent immunometric assay (Immulite 2000; Siemens AG).
S-glucose was assayed by UV photometry (Roche Modular). Se-
rum total cholesterol, high-density lipoprotein (HDL), low-den-
sity lipoprotein (LDL), triglycerides, and HbA1c were analyzed
by standard procedures at Haukeland University Hospital (Ber-
gen, Norway). Samples suited for HbA1c analysis were available
only for 14 Norwegian patients. C-terminal crosslinking telo-
peptides of type 1 collagen (CTX1) was analyzed by immunosor-
bent assay (ELISA kit; IDS) and N-propeptide of type 1 collagen
(P1NP) by competitive RIA (Origon Diagnostica Oy). CBG,
CTX1, and P1NP were analyzed at the Hormone Laboratory at
Oslo University Hospital. Otherwise, all analyses were per-
formed at Haukeland University Hospital.
Questionnaires
At each visit, the patients completed the two generic HRQoL
questionnaires Short-Form 36 (SF-36) (27) and Psychological
General Well-being Index (PGWBI) (28), and the AD-Specific
Quality-of-Life Questionnaire (AddiQoL) questionnaire, com-
prising 30 items with scoring algorithms as described elsewhere
(29). Higher scores indicate higher level of HRQoL (score range
30–120). To measure subjective sleep quality and disturbances
during the past month, the patients completed the Pittsburgh
Sleep Quality Index (PSQI) at each visit, which consists of 16
items producing seven component scores and a total index score
ranging from 0 to 21 (30). Higher scores indicate more sleeping
problems; a score above 5 is indicative of poor sleep.
Sleep registration
The study participants completed a 7-day actigraph recording
after 8 weeks on both treatments. The actigraph continuously
records information about intensity and frequency of movement.
The participants were asked to press a button to indicate time for
lights off and lights on. The actigraphs AW4 (Norway), AW7
(Sweden) (Actiwatch, Cambridge Neurotechnology Ltd), and
Actiwatch 2 (Sweden) (Respironics/Phillips) were used and were
analyzed with the actiwatch sleep analysis (AW4 and AW7) and
actiware software (Actiwatch 2). Time in bed, sleep time, wake
time, sleep efficiency, sleep-onset latency, sleep bouts, wake
bouts, and fragmentation were chosen as parameters for analy-
sis. In parallel with the actigraph recordings, a sleep diary for the
period was administered. From the sleep diaries, data on sleep
onset latency, total sleep time, number of awakenings, and sleep
quality were analyzed.
Statistical analysis
All P values were two sided, and values of P  .05 were
considered statistically significant. Data are given as percent-
ages, medians, or means together with a variability measure. The
area under the curve (AUC) for salivary profiles was calculated
by the composite trapezoidal rule and was reported for 24-hour
(AUC24h) as well as for daytime (AUC08–24) and nighttime
(AUC24–08) for each patient and for each treatment arm. Sta-
tistical analysis of paired data (24 h urine) was done by Wilcoxon
signed rank test.
To estimate differences in metabolism, HRQoL, and sleep
between CSHI and OHC treatments, a linear mixed-effects
model for repeated measures was used (31). Our model defined
treatment, visit time, treatment sequence, treatment period, and
treatment-by-time interaction as fixed effects. To account for the
intraindividual correlation between repeated measures, a ran-
dom effect with patients nested within sequence of treatment was
specified. Because of skewed distributions, several variables
from the SF-36 domain, glucose, homeostasis model assessment
(HOMA) index, and CTX-1 were transformed as recommended
(32). To investigate treatment-by-time effects on metabolism,
HRQoL, and sleep, we used the likelihood ratio test by compar-
ing the log-likelihood between models with and without the
treatment-by-time term. To obtain P for trend in means within
treatment groups, the effect of time was included as a linear term
in the mixed effect model using the z-test. To obtain P for model-
predicted mean differences between treatment groups for differ-
ent visit time, we performed a post hoc test for pairwise com-
parisons (z-test).
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Results
Participants
Fifty-five patients were screened for participation. Of
these, 18 were excluded at screening or during the dose
adjustment period. The reasons for exclusion were lack of
adherence to the study protocol (n  6), pregnancy (n 
2), technical difficulty with pump gear (n  3), plaster
allergy (n  1), lack of time to participate (n  1), or
interference of pump treatment with work or sports ac-
tivities (n  3). One patient was excluded because this
individual was diagnosed with a chronic neurological dis-
ease and another one because of inexplicably low salivary
cortisol levels on CSHI, regardless of dose adjustment.
Thirty-seven patients were randomized and 32 completed
the trial. The investigators withdrew two patients: one
became pregnant and one refused to adhere to the pre-
scribed doses (CSHI). Three patients withdrew consent,
one because of plaster allergy (CSHI), one because of lack
of time for the study (OHC), and one because of technical
problems with the pump (CSHI; data from visits A–E were
included in the study). Hence, data from 33 patients were
included in further analyses (Supplemental Table 1, pub-
lished on The Endocrine Society’s Journals Online web site
at http://jcem.endojournals.org). The mean age was 48
(SD 12) years, the mean AD duration 12.4 (SD 10.1) years,
and 25 patients (75.8%) were female.
Six females received androgen replacement and three
estrogen replacement. Fifteen patients (45%) were Swed-
ish and 18 (55%) were Norwegian. The majority were
full-time workers (60.6%) and 12.1% did not work. Only
21% did not engage in physical activity, whereas 55%
exercised more than 3 hours per week. All the Swedish
patients received pretrial glucocorticoid replacement ther-
apy with hydrocortisone; all the Norwegians were treated
with cortisone acetate. Most of the patients received glu-
cocorticoids twice (n  13) or thrice (n  14) daily and six
patients received four or five daily doses. Fourteen patients
were treated for hypothyroidism (42%); 24 had other co-
morbidities. Only hay fever (n  5), bronchial asthma (n 
2), hypercholesterolemia (n  3), osteopenia (n  3), pre-
mature ovarian failure (n  2), and hypertension (n  2)
occurred in more than one patient.
Glucocorticoid levels and effects on the HPA axis
and glucocorticoid metabolism
The OHC doses (mean 0.26 mg/kgd; SD 0.08) were
slightly lower than the CSHI doses (mean 0.31 mg/kgd;
SD 0.07); both were lower than the hydrocortisone equiv-
alent pretrial doses (mean 0.36 mg/kgd, SD 0.13) (see
Supplemental Table 1). Morning ACTH levels decreased
during CSHI and remained high during OHC (Figure 2A).
During CSHI, the morning serum cortisol and cortisone
levels were within the reference range (25), in contrast to
Figure 2. Treatment effects on the HPA axis. A, Morning ACTH levels. B, Morning cortisol levels. C, Twenty-four-hour salivary cortisol curves.
D, Twenty-four-hour salivary cortisone curves. The black line represents CSHI, and the gray line represents OHC. Error bars represent 95% CIs. For
AUC results, see Supplemental Figure 1.
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the low levels found on OHC (Figure 2B). The salivary
cortisol and cortisone day curves are presented in Figure 2,
C and D. No between-treatment difference was seen in the
AUC24h for salivary cortisol, but the daytime AUC08–24
was higher for OHC and nighttime AUC24–08 was higher
for CSHI (Supplemental Figure 1). The AUC24h for sali-
vary cortisone was higher for CSHI than for OHC. Fur-
thermore, nighttime salivary cortisone AUC was higher
with CSHI treatment, but no difference was found be-
tween the treatments during daytime.
Urine metabolites and calculated enzyme indices are
shown in Table 1. Both 24-hour urinary excretions of cor-
tisol and cortisone were significantly higher during CSHI
than during OHC, whereas no between-treatment differ-
ences were found in total cortisol metabolites. Estimated
enzyme indices of 5-reductase, 5-reductases, and
CYP3A4 were elevated in OHC compared with CSHI as
well as when compared with healthy controls in a previous
study (33) (Figure 3).
Effects on metabolism
No significant differences between treatments in weight,
waist to hip ratio, or BP were observed, although there was
a tendency toward an increase in weight and body mass
index (BMI) with CSHI (Table 2). No between-treatment
differences were found in insulin, insulin C-peptide, or
HOMA index; however, there was a trend toward an in-
creased HOMA index with CSHI. Morning glucose levels
increased with CSHI and were significantly higher on
CSHI than on OHC (P  .004). HbA1c (n  14) decreased
over time in both treatments (both P for trend  .019).
There were no significant differences in levels of choles-
terol, HDL, LDL, and triglycerides. Both CTX1 and P1NP
declined during CSHI treatment, whereas on OHC treat-
ment, CTX1 was stable and P1NP increased. The levels
were within the reference range and the differences small
(Table 2).
Effects on HRQoL
The HRQoL scores remained unchanged during OHC
treatment (Supplemental Table 2). During CSHI, the Ad-
diQoL scores increased significantly and were better than
the AddiQoL scores with OHC (Figure 4). The AddiQoL
short version scores displayed a similar pattern. Of the
other HRQoL indices, the PGWBI vitality score and (total)
index increased significantly with CSHI, and only the vi-
tality score was significantly different between treatments.
The SF-36 physical function score was better with CSHI
than with OHC.
Effects on sleep
We found no significant between-treatment difference
by actigraphy. Data from the sleep diaries suggested
shorter sleep time with CSHI than with OHC, but this
finding was not verified by actigraphy (Supplemental Ta-
ble 3). The PSQI global score increased during CSHI treat-
ment [baseline mean 4.8, confidence interval (CI) 3.7, 5.8
vs a 12-wk mean of 5.6 (CI 4.5, 6.7), P for interaction 
.016 when compared with OHC]. Examining the seven
underlying PSQI component scores, only self-reported
Table 1. Twenty-Four-Hour Urinary Excretion of Cortisol Metabolites and Calculated Enzyme Indices
OHC (n  31) CSHI (n  29)
Wilcoxon Signed Rank
P ValueMedian Range Median Range
Free cortisol 73.5 22.4, 814 453.7 196.0, 1822 0.001
Free cortisone 230.8 86.3, 913 414.7 238.2, 1029 .001
6-Hydroxycortisol 529.4 103.8, 2879 471.9 75.8, 1340 .452
THF 9216 4056, 20 712 10 940 5695, 20 849 .002
AlloTHF 6149 584.0, 13 463 4715 331.7, 10 281 .001
THE 15667 7696, 33 494 16 772 7091, 29 603 .285
Total metabolites 30852 15 318, 57 899 34 805 16 978, 62 454 .219
11-HSD2 activitya 3.45 0.81, 7.61 0.95 0.42, 2.19 .001
CYP3A4 activityb 6.88 2.20, 14.15 1.03 0.10, 3.21 .001
Overall 11-HSD activityc 0.95 0.49, 1.70 0.96 0.40, 1.70 .285
5-Reductase activityd 85.7 7.0, 529.0 8.5 0.91, 19.9 .001
5-Reductase activity (cortisol)e 117.7 25.5, 612.8 24.3 11.4, 44.0 .001
5-Reductase activity (cortisone)f 56.6 21.6, 184.2 36.4 16.8, 62.0 .001
Abbreviations: alloTHF, allo-tetrahydrocortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol. All values are given as nanomoles per 24 hours.
a Cortisone to cortisol calculated ratio.
b 6-Hydroxycortisol to cortisol calculated ratio.
c (THF  a-THF) to THE calculated ratio.
d a-THF to cortisol calculated ratio.
e THF to cortisol calculated ratio.
f THE to cortisone calculated ratio.
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sleep length and self-reported time in bed scores increased
during CSHI.
Adverse events
During OHC 22 adverse events (AEs) were reported,
of which one was probably related to the study drug
(nausea indicating insufficient dosage) and four as possibly
related: mild headache (n  1), orthostatism (n  1), and
fatigue (n  2). One serious AE was recorded, ie, hospi-
talization because of gastroenteritis. During CSHI treat-
ment, 24 AEs were registered, of which four probably
related to the treatment: rubor and itching at injection site
(n  3) and fatigue (n  1). Later it was discovered that the
fatigue was due to technical problems with the pump gear,
leading to periods without active infusion of the study
drug. No patients in the CSHI treatment had any serious
AEs.
Discussion
This study shows that CSHI can safely reestablish the cir-
cadian cortisol rhythm and normalize morning ACTH lev-
els in AD patients, which is in sharp contrast to the typical
daytime cortisol peaks and troughs and elevated morning
ACTH seen with OHC treatment. Notably, OHC yielded
major alterations in the pattern of glucocorticoid metab-
olites and metabolic enzyme activities, whereas CSHI re-
stored glucocorticoid metabolism close to normal.
There is no optimal biomarker for follow-up of AD
patients in glucocorticoid replacement therapy. ACTH
measurement is not useful on OHC because elevated
morning ACTH levels are inevitable because of the night-
time cortisol pause. However, with CSHI or other phys-
iological therapies the ACTH levels might become a useful
biomarker for individualization of doses. Whether there is
any benefit in normalizing ACTH levels apart from im-
proving pigmentation is not known. However, recent re-
search on the melanocortin receptor system has demon-
strated that ACTH and other proopiomelanocortin-derived
metabolites have multiple effects (eg, regulation of appetite
and behavior, immune modulation, and modulation of li-
polysis) (34–36). Thus, normalization of ACTH could
have important albeit not-yet-defined effects on AD
patients.
Because hydrocortisone is administered differently with
CSHI and OHC, we could not assume equal daily doses
with the two treatments. Notably, the doses were reduced
from before inclusion in both treatment arms. The esti-
Figure 3. Cortisol metabolism. Enzyme indices were estimated from 24-hour urine cortisol metabolites. Overall HSD activity included (THF
allo-THF)/THE. HSD2 activity included cortisone to cortisol ratio. 5-Reductase activity included allo-THF/cortisol. 5-Reductase activity (cortisol)
included THF/cortisol. 5-Reductase activity (cortisone) included THE/cortisone. CYP3A4 activity included 6-cortisol/cortisol. The black columns
represent CSHI, and the gray columns represent OHC. Error bars represent 95% CIs. The broken line (F) indicates levels from healthy controls in a
recent study from Boonen et al (33). HSD2, hydroxysteroid dehydrogenase type II; THFallo-THF/THE, tetrahydrocortisol plus allotetrahydrocortisol
to tetrahydrocortisone.
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Baseline 33 4.8 (4.6, 5.0) 32 4.7 (4.5, 4.8) 0.10 (0.29, 0.09) .303 .004
12 wk 33 4.8 (4.6, 4.9) 32 5.0 (4.9, 5.2) 0.27 (0.76, 0.46) .006
P for trendd 0.831 0.001
HbA1c
Baseline 14 5.2 (5.1, 5.3) 14 5.3 (5.1, 5.4) 0.039 (0.034, 0.11) .298 1.00
12 wk 14 5.1 (5.0, 5.2) 14 5.2 (5.0, 5.3) 0.039 (0.034, 0.11) .298
P for trendd 0.019 0.019
Cholesterol
Baseline 33 5.1 (4.8, 5.4) 32 5.3 (5.0, 5.7) 0.29 (0.03, 0.54) .026 .966
12 wk 33 5.3 (5.0, 5.6) 32 5.5 (5.1, 5.8) 0.24 (0.01, 0.49) .064
P for trendd 0.179 0.344
HDL
Baseline 33 1.7 (1.5, 1.9) 32 1.7 (1.5, 2.0) 0.02 (0.08, 0.12) .655 .242
12 wk 33 1.7 (1.5, 1.9) 32 1.8 (1.5, 2.0) 0.24 (0.12, 0.07) .633
P for trendd 0.261 0.839
LDL
Baseline 33 3.2 (2.9, 3.5) 32 3.3 (3.0, 3.6) 0.13 (0.87, 0.34) .246 .528
12 wk 33 3.2 (2.9, 3.5) 32 3.4 (3.1, 3.7) 0.28 (0.07, 0.50) .009
P for trendd 0.966 0.144
Triglycerides
Baseline 33 1.0 (0.9, 1.1) 32 1.1 (0.9, 1.3) 0.17 (0.02, 0.32) .028 .060
12 wk 33 1.1 (0.9, 1.2) 32 1.0 (0.8, 1.2) 0.04 (0.19, 0.11) .583
P for trendd 0.698 0.973
Insulin C-peptide
Baseline 31 0.7 (0.5, 0.8) 32 0.7 (0.6, 0.9) 0.03 (0.09, 0.15) .604 .283
12 wk 32 0.6 (0.5, 0.8) 31 0.8 (0.6, 1.0) 0.13 (0.02, 0.25) .027
P for trendd 0.385 0.417
Insulin
Baseline 31 8.1 (5.0, 11.3) 32 9.5 (5.6, 13.3) 1.21 (2.50, 4.92) .523 .524
12 wk 32 9.6 (5.9, 13.3) 31 11.3 (5.2, 17.4) 1.71 (1.97, 5.41) .362
P for trendd 0.440 0.303
HOMA index
Baseline 31 1.8 (1.1, 2.5) 32 2.0 (1.2, 2.8) 0.20 (0.74, 1.13) 0.678 .186
12 wk 32 2.1 (1.2, 3.0) 31 2.6 (1.2, 4.0) 0.45 (0.48, 1.39) 0.340
P for trendd 0.490 0.011
Waist to hip ratio
Baseline 33 0.9 (0.8, 0.9) 33 0.8 (0.8, 0.9) 0.007 (0.02, 0.01) 0.360 .242
12 wk 32 0.8 (0.8, 0.9) 32 0.8 (0.8, 0.9) 0.003 (0.01, 0.02) 0.667
P for trendd 0.535 0.463
BMI
Baseline 33 25.4 (24.2, 26.7) 33 25.7 (24.3, 27.0) 0.26 (0.004, 0.52) 0.054 .085
12 wk 33 25.3 (24.0, 26.6) 32 25.8 (24.5, 27.2) 0.67 (0.41, 0.94) .001
P for trendd 0.291 0.037
Weight
Baseline 33 74.3 (69.8, 78.8) 33 75.1 (70.1, 80.1) 0.84 (0.05, 1.64) .04 .114
12 wk 33 73.9 (69.3, 78.5) 32 75.8 (70.8, 80.7) 2.01 (1.21, 2.81) .001
P for trendd 0.345 0.05
Systolic BP
Baseline 33 111.6 (107.6, 115.6) 33 113.1 (109.0, 117.2) 1.56 (2.37, 5.49) .437 .731
12 wk 33 115.5 (112.0, 119.1) 32 114.6 (110.8, 118.4) 0.65 (4.59, 3.30) .747
P for trendd 0.040 0.336
Diastolic BP
Baseline 33 75.1 (72.9, 77.3) 33 75.2 (72.7, 77.6) 0.06 (2.52, 2.40) .962 .940
12 wk 33 75.7 (73.6, 77.8) 32 75.2 (73.1, 77.2) 0.49 (2.96, 1.98) .697
P for trendd 0.698 0.973
P1NP
Baseline 33 60.0 (51.0, 69.0) 32 64.1 (54.1, 74.0) 5.34 (0.24, 10.93) .061 .001
12 wk 33 68.5 (58.8, 78.3) 33 53.2 (44.5, 62.1) 15.19 (20.71, 9.67) .001
P for trendd 0.002 0.001
CTX1
Baseline 33 0.46 (0.4, 0.5) 32 0.44 (0.4, 0.5) 0.85 (1.93, 0.24) .746 .007
12 wk 33 0.49 (0.4, 0.6) 33 0.42 (0.3, 0.5) 0.62 (0.45, 1.70) .001
P for trendd 0.104 0.024
(Continued)
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mated enzyme indices were significantly higher in OHC
than in CSHI and in healthy controls (37). This difference
indicates major enzyme induction when hydrocortisone is
administered orally, which is avoided when administered
parenterally. The OHC doses were slightly lower than
CSHI doses, but the salivary cortisol AUC24h was similar
on both treatments. However, salivary cortisone might
reflect free serum cortisol levels in serum better than sal-
ivary cortisol (38). Salivary cortisone AUC24h, and 24-
hour urine cortisol were significantly higher and indicate
higher hydrocortisone bioavailability on CSHI than on
OHC. There were, however, no differences in the total
level of urinary glucocorticoids and their metabolites on
the two treatments. Furthermore, there was a trend to-
ward a minor increase in BMI on CSHI, albeit no signif-
icant between-treatment difference; and morning glucose
levels were significantly higher with CSHI.
Likewise, there was a significant trend toward higher
morning HOMA index on CSHI but no between-treat-
ment difference. Otherwise, HbA1c levels decreased with
both treatments and no changes were found in other pa-
rameters such as waist to hip ratio, BP, or lipids. Taken
together, the results suggest that the CSHI starting dose
might have been even lower and closer to the estimated
normal production (18, 39). Based on this and the analyses
of 24-hour glucocorticoid profiles in a subgroup (manu-
script in preparation), we have revised the dosing algo-
rithm with the highest dosing interval delayed by 1 hour,
producing a 9% reduction of the start dose. The revised
CSHI dosing algorithm (8:00 AM to 2:00 PM 0.5 mg/m2d,
2:00–8:00 PM 0.2mg/m2d,8:00 PM to3:00 AM 0.05mg/m2d
and3:00–8:00 AM 1mg/m2d) reduces the startingdose from
10.5 to 9.6 mg/m2d.
Although this study did not have statistical power and
the proper design to reach firm conclusions on HRQoL
and sleep effects, the observed improvement of AddiQoL
scores suggests that CSHI diminishes fatigue in AD. The
generic questionnaires demonstrated significant HRQoL
improvement only in the vitality (PGWBI) and the physical
function (SF-36) subscales. This finding indicates superior
responsiveness of AddiQoL over generic questionnaires
and suggests that it might detect changes over time better
than those two generic questionnaires. Thus, our results
indicate that replicating the circadian cortisol pattern by
CSHI might improve HRQoL. The effects on HRQoL in
the current study were not as striking as in the pilot trial
(24), but whereas the pilot study included only patients
with poor functioning, the present study included pa-
tients, regardless of HRQoL status. Patients who are func-
tioning well with OHC may perceive CSHI as complicated
and disturbing, whereas patients with poor functioning
may experience significant gain and readily accept CSHI
treatment. The sleep diaries and the PSQI suggested re-
duced sleep time with CSHI, but this was not verified by
actigraphy. Furthermore, sleep time for both treatments
were similar to findings in a Norwegian reference popu-
lation (40), and the PSQI scores were better in both treat-
ment groups than in a healthy control group in another
study (41). Finally, it is an interesting observation that the
reduction from the pretrial doses both in the CSHI and
OHC arms did not adversely affect HRQoL.
The open-label crossover design implies important lim-
itations to the interpretation of the treatment effects. Most
likely, the primary outcome ACTH and the metabolic pa-
rameters are not severely affected by placebo effects. The
washout period of 2 months cannot completely exclude
carry-over effects between the treatments, but this might
be attenuated by the randomization of treatment sequence.
However, caution is required when interpreting effects on
subjective HRQoL and sleep scores. The variation of the
outcome parameters in AD and the expected effects of
CSHI were not known prior to this study, rendering power
calculation difficult. The limited number of participants
implies low statistical power and risk of type II error when
effect sizes are small. Furthermore, although it is not sur-



















Baseline 33 1095.9 (1025.8, 1165.9) 32 1105.9 (1036.6, 1175.2) 12.8 (34.9, 60.6) .598 .844
12 wk 33 1093.2 (1022.1, 1164.2) 33 1116.3 (1031.1, 1201.6) 19.6 (27.6, 66.7) .416
P for trendd 0.910 0.869
Baseline indicates start of each treatment type.
a Predicted mean difference was obtained by using linear mixed-effect models with a random intercept.
b P for difference was obtained by post hoc test for pairwise comparisons.
c P for interaction was obtained by the likelihood ratio test.
d P for trend within treatment groups was obtained by incorporating visit time visit time as a continuous model term in the regression model.
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the study prior to randomization considering experience
with insulin pump treatment (42), this could suggest se-
lection bias. However, the mean baseline HRQoL scores
in the randomized patients were better than the scores in
previous cross-sectional studies (1, 2). Both in AD and
diabetes mellitus, pump treatment requires a capable and
willing patient, and proper patient education and fol-
low-up are mandatory. Most importantly and despite any
limitations associated with the study design, the study
demonstrates that CSHI is a safe and reliable mode of
glucocorticoid replacement and thus an attractive treat-
ment option in selected patients.
In conclusion, CSHI produced a more physiological
circadian cortisol biorhythm than conventional therapy
and induced normalization of morning ACTH and corti-
sol levels, restoration of nighttime cortisol levels, and
changes in glucocorticoid metabolism resembling healthy
individuals. CSHI proved safe and may eventually become
a treatment option for selected patients with adrenal in-
sufficiency that function poorly on conventional thera-
pies. Furthermore, the modified-release oral therapies and
the current CSHI dosing schedule may create a smooth
circadian cortisol profile, but the normal biorhythm also
includes an ultradian rhythm superimposed on the circa-
dian profile (43). Future CSHI trials should aim at repli-
cating the full ultradian rhythm, which could possibly fur-
ther improve outcome for AD patients.
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